Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 DOTA-Zoledronate - ITM Medical Isotopes GmbH

Drug Profile

Lutetium-177 DOTA-Zoledronate - ITM Medical Isotopes GmbH

Alternative Names: DP-4411; ITM-41; n.c.a Lutetium-177 DOTA-Zoledronate; n.c.a. 177Lu-DOTA-Zoledronate; n.c.a. 177Lu-Zoledronate

Latest Information Update: 29 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johannes Gutenberg-University Mainz
  • Developer ITM Medical Isotopes GmbH
  • Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone metastases; Osteosarcoma

Most Recent Events

  • 27 Dec 2021 Lutetium- 177 DOTA-Zoledronate licensed to Grand Pharmaceutical in mainland China, Hong Kong, Macau and Taiwan
  • 21 Dec 2021 ITM Isotope Technologies and Australian Nuclear Science and Technology Organisation agrees on licensing and supply agreement for N.c.a. 177Lu
  • 01 Oct 2021 Phase-I development in Bone metastases is ongoing in Germany (Isotopen Technologien Munchens pipeline, October 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top